From multidrug-resistant to extensively drug-resistant tuberculosis in Lisbon, Portugal: The stepwise mode of resistance acquisition

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 1, 2013, Pages 27-33

  Perdigão, João ^a   Macedo, Rita ^a,b   Silva, Carla ^a   Machado, Diana ^c   Couto, Isabel ^c,d   Viveiros, Miguel ^c   Jordao, Luisa ^e   Portugal, Isabel ^a  

^a RESEARCH INSTITUTE FOR MEDICINES IMED ULISBOA   (Portugal)

^b Public Health Department   (Portugal)

^c INSTITUTO DE HIGIENE E MEDICINA TROPICAL   (Portugal)

^d UNIVERSIDADE NOVA DE LISBOA   (Portugal)

^e NATIONAL INSTITUTE OF HEALTH DR RICARDO JORGE   (Portugal)

Author keywords

Amikacin; Cross resistance; Kanamycin; Lisboa family

Indexed keywords

AMIKACIN; BACTERIAL PROTEIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; EIS PROTEIN; RRS PROTEIN; TLYA PROTEIN; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; GENE CLUSTER; GENE MUTATION; GENOTYPE; MULTIDRUG RESISTANT TUBERCULOSIS; NONHUMAN; PORTUGAL; PROMOTER REGION;

DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; MYCOBACTERIUM TUBERCULOSIS; PORTUGAL; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84871220844     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks371     Document Type: Article

References (23)

1. Maus CE, Plikaytis BB, Shinnick TM. Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2005; 49: 3192-7.
2. Maus CE, Plikaytis BB, Shinnick TM. Mutation of tlyA confers capreomycin resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2005; 49: 571-7.
3. Manissero D, Fernandez de la Hoz K. Surveillance methods and case definition for extensively drug resistant TB (XDR-TB) and relevance to Europe: summary update. Euro Surveill 2006; 11: pii=E061103.1.
4. WHO. Multidrug and Extensively Drug-Resistant TB (M/XDR-TB): 2010 Global Report on Surveillance and Response. Geneva: WHO, 2010. WHO Publication no. WHO/HTM/TB/2010.3.
5. Perdigao J, Macedo R, Silva C et al. Tuberculosis drug-resistance in Lisbon, Portugal: a 6-year overview. Clin Microbiol Infect 2011; 17: 1397-402.
6. Portugal I, Covas MJ, Brum L et al. Outbreak of multiple drug-resistant tuberculosis in Lisbon: detection by restriction fragment length polymorphism analysis. Int J Tuberc Lung Dis 1999; 3: 207-13.
7. Direcção Geral de Saúde. Relató rio para o Dia Mundial da Tuberculose. Lisbon: Direcção Geral de Saúde, Ministério da Saúde, 2011.
8. Perdigao J, Macedo R, Joao I et al. Multidrug-resistant tuberculosis in Lisbon, Portugal: a molecular epidemiological perspective. Microb Drug Resist 2008; 14: 133-43.
9. Perdigao J, Macedo R, Malaquias A et al. Genetic analysis of extensively drug-resistant Mycobacterium tuberculosis strains in Lisbon, Portugal. J Antimicrob Chemother 2010; 65: 224-7.
10. Portugal I, Maia S, Moniz-Pereira J. Discrimination of multidrug-resistant Mycobacterium tuberculosis IS6110 fingerprint subclusters by rpoB gene mutation analysis. J Clin Microbiol 1999; 37: 3022-4.
11. Chen W, Biswas T, Porter VR et al. Unusual regioversatility of acetyltransferase Eis, a cause of drug resistance in XDR-TB. Proc Natl Acad Sci USA 2011; 108: 9804-8.
12. Zaunbrecher MA, Sikes RD Jr, Metchock B et al. Overexpression of the chromosomally encoded aminoglycoside acetyltransferase eis confers kanamycin resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci USA 2009; 106: 20004-9.
13. Rusch-Gerdes S, Pfyffer GE, Casal M et al. Multicenter laboratory validation of the BACTEC MGIT 960 technique for testing susceptibilities of Mycobacterium tuberculosis to classical second-line drugs and newer antimicrobials. J Clin Microbiol 2006; 44: 688-92.
14. Supply P, Lesjean S, Savine E et al. Automated high-throughput genotyping for study of global epidemiology of Mycobacterium tuberculosis based on mycobacterial interspersed repetitive units. J Clin Microbiol 2001; 39: 3563-71.
15. Martin A, Camacho M, Portaels F et al. Resazurin microtiter assay plate testing of Mycobacterium tuberculosis susceptibilities to second-line drugs: rapid, simple, and inexpensive method. Antimicrob Agents Chemother 2003; 47: 3616-9.
16. Martin A, Paasch F, Docx S et al. Multicentre laboratory validation of the colorimetric redox indicator (CRI) assay for the rapid detection of extensively drug-resistant (XDR) Mycobacterium tuberculosis. J Antimicrob Chemother 2011; 66: 827-33.
17. Mitchison D, Davies G. The chemotherapy of tuberculosis: past, present and future. Int J Tuberc Lung Dis 2012; 16: 724-32.
18. Beckert P, Hillemann D, Kohl TA et al. rplC T460C identified as a dominant mutation in linezolid-resistant Mycobacterium tuberculosis strains. Antimicrob Agents Chemother 2012; 56: 2743-5.
19. Richter E, Rusch-Gerdes S, Hillemann D. First linezolid-resistant clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2007; 51: 1534-6.
20. Engstrom A, Morcillo N, Imperiale B et al. Detection of first- and second-line drug resistance in Mycobacterium tuberculosis clinical isolates by pyrosequencing. J Clin Microbiol 2012; 50: 2026-33.
21. Campbell PJ, Morlock GP, Sikes RD et al. Molecular detection of mutations associated with first- and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2011; 55: 2032-41.
22. Feuerriegel S, Cox HS, Zarkua N et al. Sequence analyses of just four genes to detect extensively drug-resistant Mycobacterium tuberculosis strains in multidrug-resistant tuberculosis patients undergoing treatment. Antimicrob Agents Chemother 2009; 53: 3353-6.
23. Kim KH, An DR, Song J et al. Mycobacterium tuberculosis Eis protein initiates suppression of host immune responses by acetylation of DUSP16/MKP-7. Proc Natl Acad Sci USA 2012; 109: 7729-34.